Vyvgart Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The vyvgart market research report is one of a series of new reports that provides vyvgart market statistics, including vyvgart industry global market size, regional shares, competitors with vyvgart market share, detailed vyvgart market segments, market trends and opportunities, and any further data you may need to thrive in the vyvgart industry. This vyvgart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing demand for targeted immunotherapy, increasing healthcare expenditure, expanding patient access to advanced treatments, supportive regulatory policies, and rising prevalence of autoimmune disorders. Major trends in the forecast period include rising investment in autoimmune research, increasing preference for biologics over traditional therapies, advancements in recombinant antibody technology, expanding therapeutic applications of IgG1 fragments, and development of subcutaneous formulations.

The growing prevalence of autoimmune diseases is anticipated to drive the expansion of the Vyvgart market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells and tissues, perceiving them as harmful. This rise in autoimmune conditions is attributed to a combination of genetic factors, environmental influences, infections, and lifestyle changes, such as diet and increased exposure to chemicals. Vyvgart (efgartigimod alfa-fcab) is used to treat autoimmune diseases such as generalized myasthenia gravis (gMG) by inhibiting the neonatal Fc receptor (FcRn) and reducing the pathogenic antibodies contributing to the disease. For example, as reported by the Myasthenia Gravis Foundation of America in August 2024, myasthenia gravis affects approximately 150 to 200 individuals per million worldwide, with an estimated 37 out of every 100,000 people in the United States living with the condition. This growing prevalence of autoimmune diseases is a key factor driving the Vyvgart market.

A notable trend in the Vyvgart market is the focus on securing regulatory approvals, which are essential for ensuring the safety and efficacy of Vyvgart in treating autoimmune diseases. Such approvals also enhance market accessibility and foster trust among healthcare providers and patients. In March 2024, argenx, a Netherlands-based immunology company, announced that VYVGART (efgartigimod alfa) received approval in Japan for the treatment of primary immune thrombocytopenia (ITP) in adults. This endorsement by Japan's Ministry of Health, Labour, and Welfare marked the first global approval of VYVGART specifically for ITP, broadening its therapeutic use beyond generalized myasthenia gravis (gMG), for which it is already approved in regions such as the United States and Europe. VYVGART, a human IgG1 antibody fragment targeting the neonatal Fc receptor (FcRn), reduces circulating IgG autoantibodies, providing a new treatment option for patients seeking effective therapies for autoimmune conditions.

In January 2022, argenx partnered with Genpharm Services to improve access to innovative treatments for generalized myasthenia gravis (gMG) in the Gulf Region. This partnership facilitates the exclusive commercialization of VYVGART (efgartigimod alfa-fcab), the first FDA-approved therapy for adult patients who are anti-AChR antibody positive. Genpharm, a UAE-based pharmaceutical company, specializes in providing accelerated access to treatments for rare diseases and specialty medications.

The key company operating in the vyvgart market is Argenx SE.

North America was the largest region in the vyvgart market in 2024. The regions covered in vyvgart report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vyvgart market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vyvgart (efgartigimod alfa-fcab) is a monoclonal antibody used in the treatment of autoimmune diseases, particularly generalized myasthenia gravis (gMG), a rare condition characterized by muscle weakness. Vyvgart works by targeting and inhibiting the neonatal Fc receptor (FcRn), thereby reducing the levels of pathogenic antibodies that contribute to the disease’s symptoms. By lowering these antibodies, Vyvgart helps to improve muscle strength and alleviate disease-related fatigue.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for vyvgart are generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular disorder that leads to muscle weakness due to disrupted communication between nerves and muscles. The drug is primarily used in adult and geriatric populations and is distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The vyvgart market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.